Tibet Pharmaceuticals (OTCPK:TBET) - Stock Price, News & Analysis

TBET Stock Overview

A specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Tibetan medicines. More details

TBET fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

High level of non-cash earnings

Does not have a meaningful market cap ($14)

Shares are highly illiquid

Tibet Pharmaceuticals, Inc. Competitors

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

MJ Holdings

OTCPK:MJNE

US$58.0

RVL Pharmaceuticals

OTCPK:RVLP.Q

US$111.0

Price History & Performance

Summary of all time highs, changes and price drops for Tibet Pharmaceuticals
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.000001
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-99.00%
5 Year Change	-99.00%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	TBET	US Pharmaceuticals	US Market
7D	0%	3.4%	1.6%
1Y	n/a	14.2%	32.3%

Return vs Industry: Insufficient data to determine how TBET performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how TBET performed against the US Market.

Price Volatility

Is TBET's price volatile compared to industry and market?
TBET volatility
TBET Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: TBET's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine TBET's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	n/a	Hong Yu	n/a

Tibet Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Tibetan medicines. The company, through its operational entity, Yunnan Shangri-La Tibetan Pharmaceutical Group Limited (YSTP), develops products in China for promoting health in human respiratory, digestive, urinary, and reproductive systems. Its commercialized products include 25 Ingredients Mandrake Pill, which is used to regulate menses to treat endometritis, pelvic inflammations, and women’s anemia; 15 Ingredients Gentiana Pill to treat bronchitis, emphysema, asthma, and hoarseness; 28 Ingredients Pinang Pill for treating cold waist hip pain, pus hematuria, and testis swelling; 18 Ingredients Chebulic (Myrobalan) Frusemide Pill for the treatment of kidney problems, lumbar and kidney pain, frequent urination, turbid urine, diabetes, and spermatorrhea; and Pomegranate Nichirin Pill to treat indigestion, back and leg pain, frequent urination, foot edema, impotence, and nocturnal emission.

Tibet Pharmaceuticals, Inc. Fundamentals Summary

How do Tibet Pharmaceuticals's earnings and revenue compare to its market cap?
TBET fundamental statistics
Market cap	US$14.00
Earnings (TTM)	US$10.82m
Revenue (TTM)	US$34.05m

0.0x

P/E Ratio

0.0x

P/S Ratio

Is TBET overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TBET income statement (TTM)
Revenue	US$34.05m
Cost of Revenue	US$19.89m
Gross Profit	US$14.17m
Other Expenses	US$3.34m
Earnings	US$10.82m

Last Reported Earnings

Sep 30, 2011

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did TBET perform over the long term?

See historical performance and comparison